<DOC>
	<DOCNO>NCT00005096</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness docetaxel treat patient stage II stage III prostate cancer .</brief_summary>
	<brief_title>Docetaxel Treating Patients With Stage II Stage III Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine pathologic complete response rate docetaxel patient high risk stage II III prostate cancer . II . Determine toxicity treatment patient . III . Correlate clinical measure response ( e.g. , symptom , physical exam , serum PSA , endorectal MRI ) pathologic response treatment patient . OUTLINE : Patients receive docetaxel IV 30 minute weekly 4 week . Treatment continue 2-6 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 19-45 patient accrue study 18 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Potential candidate radical prostatectomy Any following : Clinical stage T3 patient Serum PSA least 20 ng/mL Gleason score 810 Clinical T2 disease either following : MRI evidence seminal vesicle involvement Gleason 4+3 cancer either 5 6 biopsy positive PATIENT CHARACTERISTICS : Age : 18 85 Performance status : CALGB 01 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Hematocrit great 30 % Platelet count great 100,000/mm3 Hepatic : SGOT bilirubin normal Renal : Not specify Other : No active infection Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy prostate cancer Endocrine therapy : No prior hormonal therapy prostate cancer Radiotherapy : No prior radiotherapy prostate cancer Surgery : See Disease Characteristics No prior surgery prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>